QLT Inc., a Canadian based biotechnology company, has announced that its oral synthetic retinoid product for the treatment of retinitis pigmentosa has been granted orphan… Read More »QLT obtains orphan drug designation for retinitis pigmentosa treatment
December 1st- EURETINA have launched an exciting new initiative to support innovation across Europe in the development of new technologies in the field of retinal… Read More »EURETINA launches new Innovation Awards for 2011
Quark Pharmaceuticals Inc., has announced the dosing of a first patient in their on-going Phase I study of QPI-1007, a synthetic siRNA targeting the pro-apoptotic… Read More »Quark initiates RNAi Phase I dosing for ocular neuro – protection
Applied Genetic Technologies Corporation, a private company based in Alachua, Florida, has announced the receipt of $1M in funding for phase II human trials in… Read More »Applied Genetic Technologies Corporation receives $1M in funding award from FDA
On August 11th Topcon Corporation of Tokyo announced the signing of an agreement to purchase the glaucoma and retina related assets of OptiMedica Inc (Santa… Read More »Topcon purchase retina and glaucoma businesses from OptiMedica
The journal Nature Medicine have reported that a number of ocular researchers have raised criticisms of a diabetic macular oedema (DME) clinical trial for using… Read More »Potential for off-label use of Lucentis following DRCR clinical results
A double blind Phase III trial in 691 patients has reported that 0.5mg Lucentis plus prompt or deferred laser therapy had a significant improvement in… Read More »Lucentis (ranibizumab) plus laser treatment for DME raises bar for new therapies
Alimera Sciences Inc (NASDAQ:ALIM), headquartered in Georgia, Atlanta have raised $72.1 million through the sale of 6.6 million shares. The specialist ophthalmics company possesses a… Read More »Diabetic macular edema company raises $72 million on NASDAQ
Topcon Medical Systems Inc. (Paramus, New Jersey) have launched a dedicated iPhone application providing a mobile version of the “EyeRoute Image Management” software. The new… Read More »First iPhone application for ophthalmic image management reaches market
A study comparing the use of bevacizumab (marketed as Avastin) and ranibizumab (marketed as Lucentis) has shown that the two “wet” AMD treatments are equally… Read More »US medical insurance firm shows no difference between Avastin and Lucentis treatments